Literature DB >> 2022223

Neutrophil-activating peptide-1/interleukin-8 detection in human urine during acute bladder inflammation caused by transurethral resection of superficial cancer and bacillus Calmette-Guérin administration.

M Bettex-Galland1, U E Studer, A Walz, B Dewald, M Baggiolini.   

Abstract

Neutrophil-activating peptide-1/interleukin-8 (NAP-1/IL-8), secreted by monocytes, macrophages and a number of other cells, acts as a chemoattractant for neutrophil leukocytes and stimulates them to produce a series of responses such as shape change, adherence, exocytosis and respiratory burst, events that are of importance in inflammation. To study the release of NAP-1/IL-8, two human models of inflammation were chosen: transurethral resection of superficial bladder cancer and the subsequent instillation of bacillus Calmette-Guérin (BCG), performed in order to reduce the recurrence rate of papillary bladder tumors. As the secretions of the bladder wall are retained in the urine, patients' urine was collected during 4-hour periods. These urine samples were chromatographed on phosphocellulose. In the elution fractions NAP-1/IL-8 was quantified by a bioassay that measured the elastase release by human neutrophils. The neutrophil-stimulating activity was further purified by reverse phase high performance liquid chromatography. Although no NAP-1/IL-8 activity could be detected in normal individuals, formation of this inflammatory cytokine was observed in patients after transurethral resection and after BCG treatment. The significance and possible use of this secretion are discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2022223     DOI: 10.1159/000473608

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  7 in total

Review 1.  Novel aspects of inflammation: interleukin-8 and related chemotactic cytokines.

Authors:  M Baggiolini
Journal:  Clin Investig       Date:  1993-10

2.  Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H Wagner; M Hess; J A Laissue; C Mueller
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

3.  Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.

Authors:  M J Stassar; P D Vegt; P A Steerenberg; A P van der Meijden; H D Meiring; M Dessens-Kroon; H G Geertzen; W den Otter
Journal:  Urol Res       Date:  1994

4.  Elevated interleukin-8 levels in the urine of patients with urinary tract infections.

Authors:  Y C Ko; N Mukaida; S Ishiyama; A Tokue; T Kawai; K Matsushima; T Kasahara
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

5.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

6.  Production of urinary tumour necrosis factors and soluble tumour necrosis factor receptors in bladder cancer patients after bacillus Calmette-Guérin immunotherapy.

Authors:  A M Jackson; A B Alexandrov; S Prescott; K James
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

7.  1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer.

Authors:  Jong-Wei Hsu; Peng-Nien Yin; Ronald Wood; James Messing; Edward Messing; Yi-Fen Lee
Journal:  Oncotarget       Date:  2013-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.